Navigation Links
Biovista und DART Therapeutics nehmen Zusammenarbeit auf, um auf Duchenne-Muskeldystrophie abzielende Medikamente neu zu positionieren
Date:3/26/2013

28;higkeiten bei der Neupositionierung von Medikamenten", sagte Aris Persidis, Präsident von Biovista. "Wir glauben, dass diese Art von Kooperationen bezeichnend für Interessengruppen ist, die sich darum bemühen, auf neuartige Weisen Therapien zu entwickeln, die direkter ihre spezifischen Bedürfnisse ansprechen, und wir freuen uns auf die Zusammenarbeit mit DART Therapeutics."

Über Biovista

Biovista ist ein nicht börsennotiertes Biotechnologie-Unternehmen, das sich auf die Ermittlung neuer Anwendungsbereiche für bereits zugelassene Medikamente sowie die Erstellung von Profilen zu ihren Nebenwirkungen spezialisiert hat, die über das entsprechende Wirkprinzip ermittelt werden. Biovista entwickelt eine eigene Produktpipeline von Medikamenten für das ZNS, die Onkologie sowie Autoimmun- und seltene Krankheiten. Biovista arbeitet mit biopharmazeutischen Unternehmen an der Erweiterung von Indikationsbereichen und der Risikobereinigung ihrer Portfolios zusammen. Sie unterstützt zudem die FDA bei der Vorhersage von Nebenwirkungen und Interessengruppen von Patienten bei der Neupositionierung von Medikamenten. (http://www.biovista.com).

Über DART Therapeutics

DART Therapeutics Inc. aus Cambridge, Massachusetts, ist ein Biotechnologie-Unternehmen, da ein neues Modell für Medikamentenentwicklung auf seltene pädiatrische neuromuskuläre Krankheiten anwendet. Beim DART-Modell haben sich Patientenstiftungen und Biotechnologie-Industrie-Veteranen zusammengeschlossen, um Einfluss auf ein zentrales Problem bei seltenen Krankheiten zu nehmen: die rasche Therapie-Entwicklung. DART konzentriert sich auf DMD, eine tödliche neuromuskuläre Erkrankung, für die es keine wirksame Behandlung gibt. (http://www.dartrx.com).

Kontakte:
Biovista, Inc.
Aris Persidis
+1
'/>"/>

SOURCE Biovista, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
2. Nile Therapeutics Reports 2011 Third Quarter Financial Results
3. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
4. Fate Therapeutics Strengthens Its iPSC Platform
5. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
6. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
7. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
8. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
9. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
10. Aratana Therapeutics Completes $15 Million Series B Financing
11. MarketsandMarkets: Acute Lymphocytic Leukemia Therapeutics Market worth $3.88 Billion by 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... IL (PRWEB) January 15, 2014 Look ... find hard-working items for the lab, from fluid handling ... Guaranteed-in-Stock (GIS)—ready to ship when you order. , ... Peristaltic Pumps , from the L/S® model for precise ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... NY (PRWEB) January 15, 2014 The Microcompetition ... a major disease. One of these latent viruses is the ... rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic inflammatory ... theory, a study found that RA patients have high concentrations ...
Breaking Biology Technology:A deeper look at interfaces 2Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3
... Physicists at the University of Pennsylvania have ... measuring the way it conducts electricity on a ... of graphene, the ultra-thin, single-atom thick carbon sheets ... silicon, the current material of choice for transistor ...
... SOUTH SAN FRANCISCO, Calif., July 31 Poniard,Pharmaceuticals, ... focused,on oncology, today announced that the Company will ... Moores UCSD Cancer Center,Translational Oncology Symposium on Friday, ... Ph.D., director of preclinical and translational medicine,for Poniard ...
... HOUSTON and OTTAWA, July 31 /PRNewswire-FirstCall/ - iNutrition, ... Fission Fruit Bars, its,new all natural line of ... http://www.fissionbars.com, and come in three varieties; Fission ... Featuring morsels of,real, delicious fruits, Fission Bars have ...
Cached Biology Technology:Penn scientists demonstrate potential of graphene films as next-generation transistors 2Penn scientists demonstrate potential of graphene films as next-generation transistors 3Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium 2iNutrition Launches New Fission Fruit Nutrition Bars 2
(Date:4/23/2014)... RICHLAND, Wash. -- Like a hungry diner ripping open ... hydrogen into electricity must tear open a hydrogen molecule. ... catalyst holding onto the two halves of its hydrogen ... into how to make the catalyst work better for ... time scientists have shown precisely where the hydrogen halves ...
(Date:4/23/2014)... French and Spanish . ... CEC released its Conservation Assessment for the Big Bend-Ro ... identifies 29 priority conservation areas in a region straddling ... areas in the states of Texas, Coahuila, and Chihuahua. ... habitats inhabited by rare and endangered plants and animals, ...
(Date:4/23/2014)... (Apr. 23 2014) A team of ... cells (hNSCs) into the brains of nonhuman primates ... and 24 months found that the hNSCs had ... not cause tumors. , The study will be ... Transplantation but is currently freely available on-line ...
Breaking Biology News(10 mins):Halving hydrogen 2Halving hydrogen 3Halving hydrogen 4Conservation priorities released for several protected areas along US-Mexico border 2Conservation priorities released for several protected areas along US-Mexico border 3Study finds long-term survival of human neural stem cells transplanted into primate brain 2
... resistance of potatoes to late blight, their most important ... by the Biotechnology and Biological Sciences Research Council and ... Transactions of the Royal Society B , on 17 ... trial, the potatoes experienced ideal conditions for late blight. ...
... dividing to maintain our body functions. At each division, our ... to be faithfully duplicated to maintain the cell,s memory of ... developed a new technology that has revealed the dynamic events ... The results are published in Nature Cell Biology . ...
... power of regenerative medicine now allows scientists to transform ... pancreas cells and even neurons. However, a method to ... life-saving therapieshas proven far more difficult. But now, scientists ... San Francisco (UCSF), have made an important breakthrough: they ...
Cached Biology News:GM spuds beat blight 2New technology detect cellular memory 2Scientists transform skin cells into functioning liver cells 2Scientists transform skin cells into functioning liver cells 3
Heavy-duty rim. Especially recommended as a titration flask. Corning5100. capacity 250 mL Special grade: student grade...
This CLS number is a new product number, created to easily match Cornings product number. If showing no availability yet, please order under the old Sigma-Aldrich number (F1676) or contact customer s...
Mouse monoclonal [YPF19] to Yersinia pestis F1 antigen ( Abpromise for all tested applications)....
... a new product number, created to ... showing no availability yet, please order ... or contact customer service for assistance. ... 11.25 6.40 in. Mfr ...
Biology Products: